Synthesis, optical properties, DNA, β-cyclodextrin interactions, and antioxidant evaluation of novel isoxazolidine derivative (ISoXD2): A multispectral and computational analysis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Synthesis and Spectroscopic Characterization of Benzimidazole-Derived Schiff Base: Investigation of Optical Properties, DNA Binding, DFT, and Molecular Docking.Molecules (Basel, Switzerland) · 2026
   Article
2. GC-MS profiling, in vitro and in silico antibacterial and antioxidant potential of crude secondary metabolites of an endophytic bacterium isolated from Enhydra fluctuans lour.Scientific reports · 2025
   Article
3. In silico Identification of Natural Compounds as Potential TrkA Inhibitors for Anticancer Drug Development.Iranian journal of pharmaceutical research : IJPR
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

8 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as